LOCA-PRAM: AI-Driven Biosensing Offers Real-Time, Point-of-Care Diagnostics

Researchers at the Carl R. Woese Institute for Genomic Biology, University of Illinois Urbana-Champaign, have developed a new diagnostic tool that combines deep learning with nanoscale imaging: LOCA-PRAM.

Scientist in blue gloves hand holding glasses slide breast tissue on out of focus cancer tissue picture background.Pathologist hand in glove holding glass organ samples.Histological examination.

Image Credit: Komsan Loonprom/Shutterstock.com

LOCA-PRAM, short for “localization with context-awareness integrated with photonic resonator absorption microscopy,” is a machine learning–powered method that streamlines biomarker detection for rapid, accurate diagnostics. By integrating AI with PRAM technology, the system bypasses the need for expert analysis, making it possible to detect diseases like cancer in real time with lab-level precision.

Addressing the Limitations of Traditional Diagnostics

Most diagnostic tests still rely on centralized labs and trained professionals, which often creates delays and limits access for many patients. While point-of-care tools like glucose meters or pregnancy tests offer convenience, they aren’t equipped to handle the complexity of diseases like cancer.

PRAM—an optical biosensing method previously developed by this research team—addresses this by using gold nanoparticles (AuNPs) to detect single biomarker molecules, such as nucleic acids and antibodies. However, interpreting PRAM’s images has historically required manual adjustments to filter out false positives caused by artifacts like dust or nanoparticle clumps.

Recognizing this hurdle, graduate student Han Lee introduced a deep learning algorithm to automate the analysis. The result: LOCA-PRAM, which brings the accuracy of lab diagnostics to point-of-care settings without requiring specialized expertise. This upgrade could dramatically speed up disease monitoring and treatment decisions, enabling results in minutes instead of days.

How LOCA-PRAM Works

At its core, LOCA-PRAM merges PRAM’s sensitivity with machine learning’s ability to parse complex data. PRAM functions by shining red LED light on a sensor surface coated with biomarker-bound AuNPs, which appear as dark spots under a microscope. Traditionally, experts had to identify which of these spots were real biomarkers and which were just noise.

Lee tackled this challenge using a clever training method: he imaged the same AuNPs using both PRAM and high-resolution scanning electron microscopy (SEM). By aligning PRAM’s dark spots with SEM’s nanometer-scale visuals, he built a highly accurate training dataset. This allowed the algorithm to distinguish true biomarkers from visual artifacts with over 99 % accuracy, even at extremely low concentrations.

By automating what was once a manual and subjective process, LOCA-PRAM enables real-time analysis without compromising precision. This is a major step forward for point-of-care diagnostics, especially in time-sensitive contexts like cancer treatment monitoring.

Broader Healthcare Impact

LOCA-PRAM’s applications are wide-ranging. For chronic illnesses such as cancer, it could allow patients to monitor biomarkers from home and alert physicians at the earliest signs of relapse. In clinics, doctors could use the system to make immediate decisions, like selecting a chemotherapy regimen based on a patient’s current biomarker profile.

Just as importantly, LOCA-PRAM holds promise for addressing healthcare disparities. Many rural or underserved populations struggle to access lab-based testing due to cost or distance. Because it’s both portable and cost-effective, LOCA-PRAM could significantly expand access to high-precision diagnostics. Future versions may even connect with smartphones to simplify use further.

Of course, challenges remain. Scaling up production and navigating regulatory pathways will be critical next steps. But with support from the NIH and NSF, the project is well-positioned to move forward.

Conclusion

LOCA-PRAM represents a promising evolution in diagnostic technology. By combining deep learning with nanoscale biosensing, it delivers lab-quality accuracy in real-world settings—no lab or expert required.

Whether for at-home cancer monitoring or rapid infection testing in clinics, this innovation meets the growing demand for accessible, real-time healthcare solutions. As interdisciplinary technologies like this continue to develop, they’ll be key to shaping a more responsive, equitable healthcare landscape.

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Nandi, Soham. (2025, June 24). LOCA-PRAM: AI-Driven Biosensing Offers Real-Time, Point-of-Care Diagnostics. AZoRobotics. Retrieved on July 01, 2025 from https://www.azorobotics.com/News.aspx?newsID=16057.

  • MLA

    Nandi, Soham. "LOCA-PRAM: AI-Driven Biosensing Offers Real-Time, Point-of-Care Diagnostics". AZoRobotics. 01 July 2025. <https://www.azorobotics.com/News.aspx?newsID=16057>.

  • Chicago

    Nandi, Soham. "LOCA-PRAM: AI-Driven Biosensing Offers Real-Time, Point-of-Care Diagnostics". AZoRobotics. https://www.azorobotics.com/News.aspx?newsID=16057. (accessed July 01, 2025).

  • Harvard

    Nandi, Soham. 2025. LOCA-PRAM: AI-Driven Biosensing Offers Real-Time, Point-of-Care Diagnostics. AZoRobotics, viewed 01 July 2025, https://www.azorobotics.com/News.aspx?newsID=16057.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.